Guedan S - Search Results

1

Genome Editing in Engineered T Cells for Cancer Immunotherapy.

Bonini C, Chapuis AG, Hudecek M, Guedan S, Magnani C, Qasim W. Bonini C, et al. Among authors: guedan s. Hum Gene Ther. 2023 Sep;34(17-18):853-869. doi: 10.1089/hum.2023.128. Hum Gene Ther. 2023. PMID: 37694593 Review.

2

Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.

Irving M, Lanitis E, Migliorini D, Ivics Z, Guedan S. Irving M, et al. Among authors: guedan s. Hum Gene Ther. 2021 Oct;32(19-20):1044-1058. doi: 10.1089/hum.2021.173. Hum Gene Ther. 2021. PMID: 34662233 Free PMC article. Review.

3

Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?

Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, Laugel B, Mantock M, Markman JL, Morris E, Quintarelli C, Rade M, Reiche K, Rodriguez-Garcia A, Rodriguez-Madoz JR, Ruggiero E, Themeli M, Hudecek M, Marchiq I. Guedan S, et al. J Immunother Cancer. 2022 May;10(5):e003487. doi: 10.1136/jitc-2021-003487. J Immunother Cancer. 2022. PMID: 35577501 Free PMC article. Review.

4

Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology.

Andreu-Saumell I, Rodriguez-Garcia A, Guedan S. Andreu-Saumell I, et al. Among authors: guedan s. Methods Mol Biol. 2024;2748:151-165. doi: 10.1007/978-1-0716-3593-3_12. Methods Mol Biol. 2024. PMID: 38070114

5

Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication.

Guedan S, Gros A, Cascallo M, Vile R, Mercade E, Alemany R. Guedan S, et al. Gene Ther. 2008 Sep;15(17):1240-5. doi: 10.1038/gt.2008.94. Epub 2008 May 29. Gene Ther. 2008. PMID: 18509378 Free PMC article.

6

A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses.

Rojas JJ, Cascallo M, Guedan S, Gros A, Martinez-Quintanilla J, Hemminki A, Alemany R. Rojas JJ, et al. Among authors: guedan s. Gene Ther. 2009 Dec;16(12):1441-51. doi: 10.1038/gt.2009.103. Gene Ther. 2009. PMID: 19710704

7

GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution.

Guedan S, Grases D, Rojas JJ, Gros A, Vilardell F, Vile R, Mercade E, Cascallo M, Alemany R. Guedan S, et al. Gene Ther. 2012 Nov;19(11):1048-57. doi: 10.1038/gt.2011.184. Epub 2011 Nov 24. Gene Ther. 2012. PMID: 22113313

8

Immobilizing A Moving Target: CAR T Cells Hit CD22.

Guedan S, Delgado J. Guedan S, et al. Clin Cancer Res. 2019 Sep 1;25(17):5188-5190. doi: 10.1158/1078-0432.CCR-19-1649. Epub 2019 Jul 2. Clin Cancer Res. 2019. PMID: 31266831

9

Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses.

Rojas JJ, Guedan S, Searle PF, Martinez-Quintanilla J, Gil-Hoyos R, Alcayaga-Miranda F, Cascallo M, Alemany R. Rojas JJ, et al. Among authors: guedan s. Mol Ther. 2010 Nov;18(11):1960-71. doi: 10.1038/mt.2010.173. Epub 2010 Aug 31. Mol Ther. 2010. PMID: 20808288 Free PMC article.

10

Emerging Cellular Therapies for Cancer.

Guedan S, Ruella M, June CH. Guedan S, et al. Annu Rev Immunol. 2019 Apr 26;37:145-171. doi: 10.1146/annurev-immunol-042718-041407. Epub 2018 Dec 10. Annu Rev Immunol. 2019. PMID: 30526160 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page